Blend Therapeutics appoints CEO
This article was originally published in Scrip
Watertown, Massachusetts-based Blend Therapeutics, a biopharmaceutical company developing two classes of targeted anti-cancer medicines for the treatment of patients with solid tumor cancers, has named Drew Fromkin president and CEO.
You may also be interested in...
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.
Infographic: As the novel coronavirus continues to cause disruption and leave casualties across the globe, In Vivo has taken a look at the activities of the life sciences sector in response. Here is a breakdown of biopharma and medtech research actions against COVID-19.